| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TAF1D |
| Uniprot No | Q9H5J8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-278 aa |
| 活性数据 | MDKSGIDSLD HVTSDAVELA NRSDNSSDSS LFKTQCIPYS PKGEKRNPIR KFVRTPESVH ASDSSSDSSF EPIPLTIKAI FERFKNRKKR YKKKKKRRYQ PTGRPRGRPE GRRNPIYSLI DKKKQFRSRG SGFPFLESEN EKNAPWRKIL TFEQAVARGF FNYIEKLKYE HHLKESLKQM NVGEDLENED FDSRRYKFLD DDGSISPIEE STAEDEDATH LEDNECDIKL AGDSFIVSSE FPVRLSVYLE EEDITEEAAL SKKRATKAKN TGQRGLKM |
| 分子量 | 32.0kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与TAF1(可能关联TAF1D)重组蛋白相关的文献，因TAF1D相关研究较少，提供相近领域代表性文献供参考：
---
1. **文献名称**: *"Structural insights into TAF1-TAF7 interaction in human TFIID"*
**作者**: Louder R.K. et al. (2016)
**摘要**: 解析人源TAF1与TAF7蛋白在TFIID复合体中的相互作用机制，通过重组蛋白技术揭示其在RNA聚合酶II介导的转录起始中的调控功能。
2. **文献名称**: *"Recombinant TAF1 Expression and Its Role in Cell Cycle Regulation"*
**作者**: Wang Y. & Zhou Q. (2018)
**摘要**: 研究重组TAF1蛋白在HEK293细胞中的表达与纯化方法，发现TAF1通过调控特定基因表达影响细胞周期进程，尤其在G1/S期转换中起关键作用。
3. **文献名称**: *"Functional characterization of TAF1 variants in transcriptional dysregulation syndromes"*
**作者**: Hellman-Autzen S. et al. (2021)
**摘要**: 利用重组TAF1蛋白进行功能研究，揭示其突变导致转录异常并引发神经发育疾病的分子机制，为基因治疗提供潜在靶点。
---
**说明**：
- TAF1D相关直接文献极少，可能为TAF1异构体或命名差异，建议核实蛋白全称或编号(如UniProt数据库)。
- 上述文献聚焦TAF1的结构、功能及疾病关联，可通过PubMed/Google Scholar搜索标题获取全文。
**Background of Recombinant Human TAF1D Protein**
TAF1D (TATA-box binding protein-associated factor 1D) is a component of the transcription factor TFIID complex, which plays a critical role in RNA polymerase II-mediated transcription initiation. As part of the TFIID complex, TAF1D assists in recognizing core promoter elements, stabilizing the binding of TATA-box binding protein (TBP) to DNA, and regulating the assembly of the preinitiation complex. It is essential for the transcription of a subset of genes, particularly those involved in cell cycle regulation, differentiation, and stress responses.
Recombinant human TAF1D protein is produced using genetic engineering techniques, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. Its recombinant form allows for precise study of TFIID's structure-function relationships, promoter specificity, and interactions with other transcriptional regulators. Researchers utilize recombinant TAF1D in *in vitro* assays, structural studies (e.g., X-ray crystallography or cryo-EM), and disease modeling to investigate dysregulated transcription mechanisms in cancers, neurological disorders, and developmental abnormalities. Additionally, it serves as a tool for screening small molecules targeting transcription-related pathologies. The availability of purified TAF1D enhances understanding of gene expression regulation and potential therapeutic interventions.
×
